Maintenance of Early Responses and Delayed Responses to Tralokinumab Treatment in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study.

Abstract

Background: An anti-interleukin-13 monoclonal antibody, tralokinumab, provided favorable efficacy and safety for atopic dermatitis (AD) in clinical trials. However, its long-term sustainability of early responses and delayed responses is unknown in real world. Objective: This study aimed to assess whether clinical outcomes achieved at week 16 of tralokinumab treatment are maintained through week 48 and whether patients without early outcomes achieve delayed outcomes. Methods: This prospective study included 143 Japanese patients with moderate-to-severe AD who received tralokinumab with topical corticosteroids. Patients who achieved an eczema area and severity index (EASI) 0f 50, EASI 75, EASI 90, EASI 100, investigator's global assessment (IGA) 0/1, or a peak pruritus-numerical rating scale (PP-NRS) 4 at week 16 were evaluated for maintenance rates of each outcome, while week 16 non-achievers were evaluated for later achievement rates at weeks 24, 36, and 48. Results: In week 16, achievers of each outcome, the week 48 maintenance rates of EASI 50, EASI 75, and EASI 90 were 100%; those of EASI 100, IGA 0/1, and PP-NRS 4 were 80.0%, 95.0%, and 90.9%, respectively. In week 16 non-achievers, week 48 achievement rates for EASI 50, EASI 75, EASI 90, and EASI 100 were 53.8%, 76.5%, 48.3%, and 12.5%, and those for IGA 0/1 and PP-NRS 4 were 45.5% and 29.6%, respectively. Conclusions: The improvements of rash or pruritus achieved at week 16 of tralokinumab treatment were mostly sustained through week 48, while some patients without early improvements achieved delayed improvements. These results support the importance of longer-term evaluation of treatment responses.